Development of target-specific treatments in multiple myeloma

British Journal of Haematology

Volumn 151, Issue 1, 2010, Pages 3-15

  Chanan Khan, Asher A ^a   Borrello, Ivan ^b   Lee, Kelvin P ^a   Reece, Donna E ^c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

bortezomib; lenalidomide; multiple myeloma; tanespimycin; thalidomide

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; ARSENIC TRIOXIDE; BORTEZOMIB; CARFILZOMIB; DEXAMETHASONE; GIVINOSTAT; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MELPHALAN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCLONAL ANTIBODY; OBLIMERSEN; PANOBINOSTAT; PERIFOSINE; POMALIDOMIDE; PREDNISONE; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN KINASE B; TANESPIMYCIN; TELOMERASE; TELOMERASE INHIBITOR; TEMSIROLIMUS; THALIDOMIDE; VORINOSTAT; ANTINEOPLASTIC AGENT;

ANEMIA; ANOREXIA; CELL DIVISION; CELL GROWTH; CLINICAL TRIAL; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HUMAN; HYPOKALEMIA; INTERSTITIAL PNEUMONIA; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HISTONE DEACETYLASE INHIBITORS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MULTIPLE MYELOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; THALIDOMIDE; PROTEASOME INHIBITORS;

EID: 77956814361     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08262.x     Document Type: Review

References (94)

1. Anderson, K.C. (2007) Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Experimental Hematology, 35, 155 162.
2. Anderson, K.C., Jagannath, S., Jakubowiak, A., Lonial, S., Raje, N., Schlossman, R., Munshi, N., Knight, R., Esseltine, D. Richardson, P.G. (2008) Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM). Journal of Clinical Oncology (ASCO Meeting Abstracts), 26, 465s. Abstract 8545.
3. Badros, A.Z., Goloubeva, O., Rapoport, A.P., Ratterree, B., Gahres, N., Meisenberg, B., Takebe, N., Heyman, M., Zwiebel, J., Streicher, H., Gocke, C.D., Tomic, D., Flaws, J.A., Zhang, B. Fenton, R.G. (2005) Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. Journal of Clinical Oncology, 23, 4089 4099.
4. Badros, A., Burger, A.M., Philip, S., Niesvizky, R., Kolla, S.S., Goloubeva, O., Harris, C., Zwiebel, J., Wright, J.J., Espinoza-Delgado, I., Baer, M.R., Holleran, J.L., Egorin, M.J. Grant, S. (2009a) Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clinical Cancer Research, 15, 5250 5257.
5. Badros, A.Z., Richardson, P.G., Albitar, M., Jagannath, S., Tarantolo, S., Wolf, J.L., Messina, M., Berman, D. Anderson, K.C. (2009b) Tanespimycin + bortezomib in relapsed/refractory myeloma patients: results from the TIME-2 study. Blood (ASH Annual Meeting Abstracts), 114, 742. Abstract 1871
6. Bahlis, N.J., McCafferty-Grad, J., Jordan-McMurry, I., Neil, J., Reis, I., Kharfan-Dabaja, M., Eckman, J., Goodman, M., Fernandez, H.F., Boise, L.H. Lee, K.P. (2002) Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clinical Cancer Research, 8, 3658 3668.
7. Baysan, A., Yel, L., Gollapudi, S., Su, H. Gupta, S. (2007) Arsenic trioxide induces apoptosis via the mitochondrial pathway by upregulating the expression of Bax and Bim in human B cells. International Journal of Oncology, 30, 313 318.
8. Burton, J.D., Ely, S., Reddy, P.K., Stein, R., Gold, D.V., Cardillo, T.M. Goldenberg, D.M. (2004) CD74 is expressed by multiple myeloma and is a promising target for therapy. Clinical Cancer Research, 10, 6606 6611.
9. Caers, J., Menu, E., De Raeve, H., Lepage, D., Van Valckenborgh, E., Van Camp, B., Alvarez, E. Vanderkerken, K. (2008) Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma. British Journal of Cancer, 98, 1966 1974.
10. Cassinelli, G., Ronchetti, D., Laccabue, D., Mattioli, M., Cuccuru, G., Favini, E., Nicolini, V., Greco, A., Neri, A., Zunino, F. Lanzi, C. (2009) Concomitant downregulation of proliferation/survival pathways dependent on FGF-R3, JAK2 and BCMA in human multiple myeloma cells by multi-kinase targeting. Biochemical Pharmacology, 78, 1139 1147.
11. ®)- thalidomide-dexamethasone (VTD) vs thalidomide-dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts), 110, 121. Abstract 73.
12. Chanan-Khan, A.A., Gharibo, M., Jagannath, S., Munshi, N.C., Anderson, K.C., DePaolo, D., Lee, K.P., Miller, K., Guild, R., Zildjian, S. Qin, A. (2008a) Phase I Study of IMGN901 in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma. Blood (ASH Annual Meeting Abstracts), 112, 1263. Abstract 3689.
13. Chanan-Khan, A.A., Munshi, N.C., Hussein, M.A., Elias, L., Benedetti, F., Smith, J., Khor, S.-P. Huff, C.A. (2008b) Results of a Phase I Study of GRN163L, a Direct Inhibitor of Telomerase, in Patients with Relapsed and Refractory Multiple Myeloma (MM). Blood (ASH Annual Meeting Abstracts), 112, 1263. Abstract 3688.
14. Chanan-Khan, A.A., Niesvizky, R., Hohl, R.J., Zimmerman, T.M., Christiansen, N.P., Schiller, G.J., Callander, N., Lister, J., Oken, M. Jagannath, S. (2009) Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. Leukaemia & Lymphoma, 50, 559 565.
15. Chen-Kiang, S., Di Liberto, M., Louie, T., Liang, J., Jayabalan, D.S., Ely, S., Moore, M.A., Niesvizky, R. Huang, X. (2008) Targeting Cdk4/6 in combination therapy of chemoresistant multiple myeloma. Journal of Clinical Oncology (ASCO Meeting Abstracts), 26, 454s. Abstract 8503.
16. Cohen, S., Haimovich, J. Hollander, N. (2009) Dendritic cell-based therapeutic vaccination against myeloma: vaccine formulation determines efficacy against light chain myeloma. Journal of Immunology, 182, 1667 1673.
17. Coiffier, B. Ribrag, V. (2009) Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies. Leukaemia & Lymphoma, 50, 1916 1930.
18. Damgaard, T., Knudsen, L.M., Dahl, I.M., Gimsing, P., Lodahl, M. Rasmussen, T. (2009) Regulation of the CD56 promoter and its association with proliferation, anti-apoptosis and clinical factors in multiple myeloma. Leukaemia & Lymphoma, 50, 236 246.
19. Dancey, J.E., Curiel, R. Purvis, J. (2009) Evaluating temsirolimus activity in multiple tumors: a review of clinical trials. Seminars in Oncology, 36 (Suppl 3 S46 S58.
20. Davenport, E.L., Moore, H.E., Dunlop, A.S., Sharp, S.Y., Workman, P., Morgan, G.J. Davies, F.E. (2007) Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood, 110, 2641 2649.
21. Deleu, S., Menu, E., Van Valckenborgh, E., Van Camp, B., Fraczek, J., Vande Broek, I., Rogiers, V. Vanderkerken, K. (2009) Histone deacetylase inhibitors in multiple myeloma. Hematology Reviews, 1, 1. e9.
22. van de Donk, N.W., Bloem, A.C., van der Spek, E. Lokhorst, H.M. (2006) New treatment strategies for multiple myeloma by targeting BCL-2 and the mevalonate pathway. Current Pharmaceutical Design, 12, 327 340.
23. Erlichman, C. (2009) Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. Expert Opinion on Investigational Drugs, 18, 861 868.
24. Farag, S.S., Zhang, S., Jansak, B.S., Wang, X., Kraut, E., Chan, K., Dancey, J.E. Grever, M.R. (2009) Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. Leukemia Research, 33, 1475 1480.
25. Fulciniti, M., Hideshima, T., Vermot-Desroches, C., Pozzi, S., Nanjappa, P., Shen, Z., Patel, N., Smith, E.S., Wang, W., Prabhala, R., Tai, Y.T., Tassone, P., Anderson, K.C. Munshi, N.C. (2009) A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clinical Cancer Research, 15, 7144 7152.
26. Galli, M., Salmoiraghi, S., Golay, J., Gozzini, A., Crippa, C., Pescosta, N. Rambaldi, A. (2010) A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Annals of Hematology, 89, 185 190.
27. Galustian, C., Meyer, B., Labarthe, M.C., Dredge, K., Klaschka, D., Henry, J., Todryk, S., Chen, R., Muller, G., Stirling, D., Schafer, P., Bartlett, J.B. Dalgleish, A.G. (2009) The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunology, Immunotherapy, 58, 1033 1045.
28. Ge, F., Lu, X.P., Zeng, H.L., He, Q.Y., Xiong, S. Jin, L. (2009) Proteomic and functional analyses reveal a dual molecular mechanism underlying arsenic-induced apoptosis in human multiple myeloma cells. J Proteome Res, 8, 3006 3019.
29. Giles, F., Fischer, T., Cortes, J., Garcia-Manero, G., Beck, J., Ravandi, F., Masson, E., Rae, P., Laird, G., Sharma, S., Kantarjian, H., Dugan, M., Albitar, M. Bhalla, K. (2006) A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clinical Cancer Research, 12, 4628 4635.
30. Glasmacher, A., Hahn, C., Hoffmann, F., Naumann, R., Goldschmidt, H., von Lilienfeld-Toal, M., Orlopp, K., Schmidt-Wolf, I. Gorschluter, M. (2006) A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. British Journal Haematology, 132, 584 593.
31. TM + thalidomide + dexamethasone (VATD) as an effective regimen in patients with refractory or relapsed multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts), 104, 659a. Abstract 2399.
32. Hsi, E.D., Steinle, R., Balasa, B., Szmania, S., Draksharapu, A., Shum, B.P., Huseni, M., Powers, D., Nanisetti, A., Zhang, Y., Rice, A.G., van Abbema, A., Wong, M., Liu, G., Zhan, F., Dillon, M., Chen, S., Rhodes, S., Fuh, F., Tsurushita, N., Kumar, S., Vexler, V., Shaughnessy, Jr., J.D., Barlogie, B., van Rhee, F., Hussein, M., Afar, D.E. Williams, M.B. (2008) CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clinical Cancer Research, 14, 2775 2784.
33. Ikeda, H., Hideshima, T., Fulciniti, M., Lutz, R.J., Yasui, H., Okawa, Y., Kiziltepe, T., Vallet, S., Pozzi, S., Santo, L., Perrone, G., Tai, Y.T., Cirstea, D., Raje, N.S., Uherek, C., Dalken, B., Aigner, S., Osterroth, F., Munshi, N., Richardson, P. Anderson, K.C. (2009) The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clinical Cancer Research, 15, 4028 4037.
34. Jagannath, S., Richardson, P.G., Zeldenrust, S., Alsina, M., Wride, K., Zeldis, J.B., Knight, R., Olesnyckyj, M. Anderson, K.C. (2008) Long-term responses observed with lenalidomide therapy for patients with relapsed or refractory multiple myeloma. Journal of Clinical Oncology (ASCO Meeting Abstracts), 26, 460s. Abstract 8525.
35. Jagannath, S., Vij, R., Stewart, K., Somlo, G., Jakubowiak, A., Trudel, S., Schwartz, R., Siegel, D., Kunkel, L. The Multiple Myeloma Research, C. (2009) Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). Journal of Clinical Oncology (ASCO Meeting Abstracts), 27, 435s. Abstract 8504.
36. Jakubowiak, A., Richardson, P., Zimmerman, T.M., Alsina, M., Kaufman, J.L., Harvey, C., Brozo, C., Kendall, T., McAllister, A., Hideshima, T., Sportelli, P., Gardner, L., Anderson, K.C. Giusti, K. (2008) Phase I results of perifosine (KRX-0401) in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts), 112, 1264. Abstract 3691.
37. Jakubowiak, A.J., Hofmeister, C.C., Campagnaro, E.L., Zimmerman, T.M., Schlossman, R.L., Lonial, S., Reece, D.E., Kaminski, M.S., Anderson, K.C. Richardson, P.G. (2009a) Lenalidomide, bortezomib, pegylated liposomal doxorubicin hydrochloride, and dexamethasone in newly diagnosed multiple myeloma: initial results of phase I/II MMRC trial. Journal of Clinical Oncology (ASCO Meeting Abstracts), 27, 438s. Abstract 8517.
38. Jakubowiak, A.J., Bensinger, W., Siegel, D., Zimmerman, T.M., Van Tornout, J.M., Zhao, C., Singhal, A. Anderson, K. (2009b) Phase 1/2 study of elotuzumab in combination with bortezomib in patients with multiple myeloma with one to three prior therapies: interim results. Blood (ASH Annual Meeting Abstracts), 114, 1491. Abstract 3876.
39. Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M.F., Fritz, L.C. Burrows, F.J. (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature, 425, 407 410.
40. Kastritis, E., Zervas, K., Symeonidis, A., Terpos, E., Delimpassi, S., Anagnostopoulos, N., Michali, E., Zomas, A., Katodritou, I., Gika, D., Pouli, A., Christoulas, D., Roussou, M., Economopoulos, T. Dimopoulos, M.A. (2008) Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS) an analysis of the Greek Myeloma Study Group (GMSG). Blood (ASH Annual Meeting Abstracts), 112, 244. Abstract 655.
41. Kastritis, E., Palumbo, A. Dimopoulos, M.A. (2009) Treatment of relapsed/refractory multiple myeloma. Seminars in Hematology, 46, 143 157.
42. Kawauchi, K., Ogasawara, T., Yasuyama, M., Otsuka, K. Yamada, O. (2009) The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anti-Cancer Agents in Medicinal Chemistry, 9, 550 559.
43. Kennah, M., Yau, T.Y., Nodwell, M., Krystal, G., Andersen, R.J., Ong, C.J. Mui, A.L. (2009) Activation of SHIP via a small molecule agonist kills multiple myeloma cells. Experimental Hematology, 37, 1274 1283.
44. Kuhn, D.J., Chen, Q., Voorhees, P.M., Strader, J.S., Shenk, K.D., Sun, C.M., Demo, S.D., Bennett, M.K., van Leeuwen, F.W., Chanan-Khan, A.A. Orlowski, R.Z. (2007) Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood, 110, 3281 3290.
45. Kumar, S., Blood, E., Oken, M.M. Greipp, P.R. (2004) Prognostic Value of Syndecan-1 in Multiple Myeloma and its Relationship with Other Prognostic Factors. Blood (ASH Annual Meeting Abstracts), 104, 660a. Abstract 2402.
46. Kyrtsonis, M.-C., Vassilakopoulos, T.P., Papadogiannis, A., Tzenou, T., Kalpadakis, C., Antoniadis, A., Dimopoulou, M.N., Siakantaris, M.P., Kokoris, S.I., Dimitriadou, E.M., Angelopoulou, M.K., Plata, E., Tsaftaridis, P. Pangalis, G.A. (2005) Serum Soluble Syndecan-1 Levels at Diagnosis Constitute an Independent Prognostic Factor of Survival in Myeloma That May Further Differentiate Patients within the ISS Stages. Blood (ASH Annual Meeting Abstracts), 106, 951a. Abstract 3404.
47. Labi, V., Grespi, F., Baumgartner, F. Villunger, A. (2008) Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy? Cell Death and Differentiation, 15, 977 987.
48. Lacy, M.Q., Hayman, S.R., Gertz, M.A., Allred, J.B., Mandrekar, S.J., Dispenzieri, A., Zeldenrust, S.R., Kumar, S., Greipp, P.R., Lust, J.A., Russell, S.J., Buadi, F., Kyle, R.A., Bergsagel, P.L., Fonseca, R., Roy, V., Mikhael, J., Stewart, A.K. Rajkumar, S.V. (2008) Pomalidomide (CC4047) plus low-dose dexamethasone (pom/dex) is highly effective therapy in relapsed multiple myeloma. Blood (ASH Annual Meeting Abstracts), 112, 320. Abstract 866.
49. Lin, P., Owens, R., Tricot, G. Wilson, C.S. (2004) Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. American Journal of Clinical Pathology, 121, 482 488.
50. Lonial, S., Vij, R., Harousseau, J., Facon, T., Kaufman, J., Mazumder, A., Moreau, P., Leleu, X., Fry, J., Singhal, A. Jagannath, S. (2009) Phase 1/2 study of elotuzumab in combination with lenalidomide and low dose dexamethasone in relapsed or refractory multiple myeloma: interim results. Blood (ASH Annual Meeting Abstracts), 114, 179. Abstract 432.
51. Lunghi, P., Giuliani, N., Mazzera, L., Lombardi, G., Ricca, M., Corradi, A., Cantoni, A.M., Salvatore, L., Riccioni, R., Costanzo, A., Testa, U., Levrero, M., Rizzoli, V. Bonati, A. (2008) Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood, 112, 2450 2462.
52. Lutz, R.J. Whiteman, K.R. (2009) Antibody-maytansinoid conjugates for the treatment of myeloma. mAbs, 1, 548 551.
53. Mahtouk, K., Cremer, F.W., Reme, T., Jourdan, M., Baudard, M., Moreaux, J., Requirand, G., Fiol, G., De Vos, J., Moos, M., Quittet, P., Goldschmidt, H., Rossi, J.-F., Hose, D. Klein, B. (2005) Syndecan-1 Is Essential for the Myeloma Cell Growth Factor Activity of EGF-Family Ligands in Multiple Myeloma. Blood (ASH Annual Meeting Abstracts), 106, 186a. Abstract 626.
54. Martin, P., Santon, A. Bellas, C. (2004) Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis. Histopathology, 44, 375 380.
55. ®) alone and in combination with dexamethasone in patients with relapsed/refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts), 112, 1268. Abstract 3700.
56. McMillin, D.W., Ooi, M., Delmore, J., Negri, J., Hayden, P., Mitsiades, N., Jakubikova, J., Maira, S.M., Garcia-Echeverria, C., Schlossman, R., Munshi, N.C., Richardson, P.G., Anderson, K.C. Mitsiades, C.S. (2009) Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Research, 69, 5835 5842.
57. Medicherla, S., Reddy, M., Ying, J., Navas, T.A., Li, L., Nguyen, A.N., Kerr, I., Hanjarappa, N., Protter, A.A. Higgins, L.S. (2008) p38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma. Anticancer Research, 28, 3827 3833.
58. Mikhael, J.R., Belch, A.R., Prince, H.M., Lucio, M.N., Maiolino, A., Corso, A., Petrucci, M.T., Musto, P., Komarnicki, M. Stewart, A.K. (2009) High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. British Journal Haematology, 144, 169 175.
59. Mitsiades, N., Mitsiades, C.S., Poulaki, V., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T.A., Treon, S.P., Munshi, N.C., Richardson, P.G., Hideshima, T. Anderson, K.C. (2002) Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proceedings of the National Academy of Sciences of the United States of America, 99, 14374 14379.
60. Mitsiades, C.S., Mitsiades, N.S., McMullan, C.J., Poulaki, V., Shringarpure, R., Hideshima, T., Akiyama, M., Chauhan, D., Munshi, N., Gu, X., Bailey, C., Joseph, M., Libermann, T.A., Richon, V.M., Marks, P.A. Anderson, K.C. (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proceedings of the National Academy of Sciences of the United States of America, 101, 540 545.
61. Mitsiades, C.S., Ocio, E.M., Pandiella, A., Maiso, P., Gajate, C., Garayoa, M., Vilanova, D., Montero, J.C., Mitsiades, N., McMullan, C.J., Munshi, N.C., Hideshima, T., Chauhan, D., Aviles, P., Otero, G., Faircloth, G., Mateos, M.V., Richardson, P.G., Mollinedo, F., San-Miguel, J.F. Anderson, K.C. (2008) Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Research, 68, 5216 5225.
62. Mitsiades, C.S., Hideshima, T., Chauhan, D., McMillin, D.W., Klippel, S., Laubach, J.P., Munshi, N.C., Anderson, K.C. Richardson, P.G. (2009) Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Seminars in Hematology, 46, 166 175.
63. Moreira, J.N., Santos, A. Simoes, S. (2006) Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality. Reviews on Recent Clinical Trials, 1, 217 235.
64. Ocio, E.M., Mateos, M.V., Maiso, P., Pandiella, A. San-Miguel, J.F. (2008) New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. The Lancet Oncology, 9, 1157 1165.
65. Palumbo, A.P., Bringhen, S., Rossi, D., Berretta, S., Montefusco, V., Peccatori, J., Galli, M., Carella, A., Omede, P., Boccadoro, M. Italian Multiple Myeloma, N. (2009) A phase III study of VMPT versus VMP in newly diagnosed elderly myeloma patients. Journal of Clinical Oncology (ASCO Meeting Abstracts), 27, 437s. Abstract 8515.
66. Parkinson, E.K. Minty, F. (2007) Anticancer therapy targeting telomeres and telomerase : current status. BioDrugs, 21, 375 385.
67. Pei, X.Y., Dai, Y. Grant, S. (2004) Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clinical Cancer Research, 10, 3839 3852.
68. Pennati, M., Folini, M. Zaffaroni, N. (2008) Targeting survivin in cancer therapy. Expert Opinion on Therapeutic Targets, 12, 463 476.
69. Phatak, P. Burger, A.M. (2007) Telomerase and its potential for therapeutic intervention. British Journal of Pharmacology, 152, 1003 1011.
70. Polson, A.G. Sliwkowski, M.X. (2009) Toward an effective targeted chemotherapy for multiple myeloma. Clinical Cancer Research, 15, 3906 3907.
71. Qazilbash, M.H., Saliba, R.M., Nieto, Y., Parikh, G., Pelosini, M., Khan, F.B., Jones, R.B., Hosing, C., Mendoza, F., Weber, D.M., Wang, M., Popat, U., Alousi, A., Anderlini, P., Champlin, R.E. Giralt, S. (2008) Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biology of Blood and Marrow Transplantation, 14, 1401 1407.
72. Reece, D.E. (2007) Management of multiple myeloma: the changing landscape. Blood Reviews, 21, 301 314.
73. van Rhee, F., Szmania, S.M., Dillon, M., van Abbema, A.M., Li, X., Stone, M.K., Garg, T.K., Shi, J., Moreno-Bost, A.M., Yun, R., Balasa, B., Ganguly, B., Chao, D., Rice, A.G., Zhan, F., Shaughnessy, Jr., J.D., Barlogie, B., Yaccoby, S. Afar, D.E. (2009) Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Molecular Cancer Therapeutics, 8, 2616 2624.
74. Richardson, P., Lonial, S., Jakubowiak, A., Jagannath, S., Raje, N.S., Avigan, D., Ghobrial, I.M., Schlossman, R.L., Mazumder, A., Munshi, N.C., Vesole, D.H., Joyce, R., Doss, D., Warren, D.L., Hayes, S.W., Kaster, S., Delaney, C., Lauria, M., Mitsiades, C., Hideshima, T., Knight, R.D., Esseltine, D.-L. Anderson, K.C. (2008a) Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a Phase I/II study. Blood (ASH Annual Meeting Abstracts), 112, 41. Abstract 92.
75. Richardson, P., Mitsiades, C., Colson, K., Reilly, E., McBride, L., Chiao, J., Sun, L., Ricker, J., Rizvi, S., Oerth, C., Atkins, B., Fearen, I., Anderson, K. Siegel, D. (2008b) Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leukaemia & Lymphoma, 49, 502 507. (Pubitemid 351298334)
76. Richardson, P., Wolf, J., Jakubowiak, A., Zonder, J., Lonial, S., Irwin, D.H., Densmore, J., Krishnan, A., Raje, N., Bar, M.H., Allerton, J.P., Schlossman, R., Ghobrial, I.M., Munshi, N.C., Martin, T., Laubach, J., Colson, K., Dean, S., Tocco, D., Steinfield, E., Kendall, T., O'Riley, K., Hideshima, T., Sportelli, P., Gardner, L. Anderson, K.C. (2008c) Phase I/II results of a multicenter trial of perifosine (KRX-0401) + bortezomib in patients with relapsed or relapsed/refractory multiple myeloma who were previously relapsed from or refractory to bortezomib. Blood (ASH Annual Meeting Abstracts), 112, 321. Abstract 870.
77. Richardson, P.G., Weller, E., Jagannath, S., Avigan, D.E., Alsina, M., Schlossman, R.L., Mazumder, A., Munshi, N.C., Ghobrial, I.M., Doss, D., Warren, D.L., Lunde, L.E., McKenney, M., Delaney, C., Mitsiades, C.S., Hideshima, T., Dalton, W., Knight, R., Esseltine, D.L. Anderson, K.C. (2009a) Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology, 27, 5713 5719.
78. Richardson, P.G., Chanan-Khan, A., Lonial, S., Krishnan, A., Carroll, M., Alsina, M., Albitar, M., Berman, D., Kaplita, S. Anderson, K. (2009b) Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: final results of a phase I/II study. American Society of Clinical Oncology (ASCO), 27, 8503.
79. Roccaro, A.M., Sacco, A., Thompson, B., Leleu, X., Azab, A.K., Azab, F., Runnels, J., Jia, X., Ngo, H.T., Melhem, M.R., Lin, C.P., Ribatti, D., Rollins, B.J., Witzig, T.E., Anderson, K.C. Ghobrial, I.M. (2009) MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood, 113, 6669 6680.
80. Rollig, C. Illmer, T. (2009) The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: a systematic review. Cancer Treatment Reviews, 35, 425 430.
81. Rosenblatt, J. Avigan, D. (2008) Cellular immunotherapy for multiple myeloma. Best Practice & Research. Clinical Haematology, 21, 559 577.
82. Santo, L., Vallet, S., Hideshima, T., Cirstea, D., Pozzi, S., Vaghela, N., Ikeda, H., Okawa, Y., Gorgun, G., Perrone, G., Calabrese, E., Squires, M.S., Ladetto, M., Munshi, N.C., Boccadoro, M., Anderson, K.C. Raje, N. (2008) AT7519, a novel small molecule multi-cyclin dependent kinase inhibitor, induces apoptosis in multiple myeloma VIA GSK3[beta]. Blood (ASH Annual Meeting Abstracts), 112, 99. Abstract 251.
83. Seidel, C., Sundan, A., Hjorth, M., Turesson, I., Dahl, I.M., Abildgaard, N., Waage, A. Borset, M. (2000) Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood, 95, 388 392.
84. Shammas, M.A., Koley, H., Bertheau, R.C., Neri, P., Fulciniti, M., Tassone, P., Blotta, S., Protopopov, A., Mitsiades, C., Batchu, R.B., Anderson, K.C., Chin, A., Gryaznov, S. Munshi, N.C. (2008) Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia, 22, 1410 1418.
85. Siegel, D.S., Krishnan, A., Lonial, S., Chatta, G., Alsina, M., Jagannath, S., Richardson, P., Hohl, R.J., Lust, J.A., Bensinger, W., Carrum, G., Moreb, J., Simic, A., Barlogie, B., Maziarz, R.T., Anderson, K.C., Lin, J., Lowe, A., Vetticaden, S. Zhu, J. (2006) Phase II trial of SCIO-469 as monotherapy (M) or in combination with bortezomib (MB) in relapsed refractory multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts), 108, 1022a. Abstract 3580.
86. Smith, E.M., Boyd, K. Davies, F.E. (2010) The potential role of epigenetic therapy in multiple myeloma. British Journal of Haematology, 148, 702 713.
87. Tai, Y.T., Dillon, M., Song, W., Leiba, M., Li, X.F., Burger, P., Lee, A.I., Podar, K., Hideshima, T., Rice, A.G., van Abbema, A., Jesaitis, L., Caras, I., Law, D., Weller, E., Xie, W., Richardson, P., Munshi, N.C., Mathiot, C., Avet-Loiseau, H., Afar, D.E. Anderson, K.C. (2008) Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood, 112, 1329 1337.
88. Tan, J., Cang, S., Ma, Y., Petrillo, R.L. Liu, D. (2010) Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. Journal of Hematology & Oncology, 3, 5.
89. Tassone, P., Gozzini, A., Goldmacher, V., Shammas, M.A., Whiteman, K.R., Carrasco, D.R., Li, C., Allam, C.K., Venuta, S., Anderson, K.C. Munshi, N.C. (2004) In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2′-deacetyl-N2′-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Research, 64, 4629 4636.
90. U.S. National Institutes of Health. 2009 A study of tanespimycin (KOS-953) in patients with relapsed-refractory multiple myeloma (TIME-2). http://clinicaltrials.gov/ct2/show/NCT00514371. Accessed 25 August 2009.
91. Vij, R., Wang, M., Orlowski, R., Stewart, A.K., Jagannath, S., Kukreti, V., Le, M.H., Kunkel, L., Siegel, D. Multiple Myeloma Research Consortium 2009) PX-171-004, a multicenter phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: an efficacy update. Journal of Clinical Oncology (ASCO Meeting Abstracts), 27, 443s. Abstract 8537.
92. Voorhees, P.M., Manges, R.F., Sonneveld, P., Somlo, G., Jagannath, S., Zweegman, S., Munteanu, M., Vermeulen, J.T., Xie, H. Orlowski, R.Z. (2008) Phase II study evaluating the efficacy and safety of CNTO328 in combination with dexamethasone for patients with relapsed/refractory multiple myeloma (MM). Journal of Clinical Oncology, 26, 8593.
93. Weber, D., Badros, A.Z., Jagannath, S., Siegel, D., Richon, V., Rizvi, S., Garcia-Vargas, J., Reiser, D. Anderson, K.C. (2008) Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: early clinical experience. Blood (ASH Annual Meeting Abstracts), 112, 322. Abstract 871.
94. Whitesell, L. Lindquist, S.L. (2005) HSP90 and the chaperoning of cancer. Nature Reviews. Cancer, 5, 761 772.